Letter to FDA on Abuse-Deterrent Formulations

/Letter to FDA on Abuse-Deterrent Formulations

Letter to FDA on Abuse-Deterrent Formulations

Dear Sir or Madam:

We are grateful for the opportunity to submit comments regarding the Development and Regulation of Abuse-Deterrent Formulations of Opioid Medications.

As a diverse group of stakeholders working together for comprehensive and balanced policies that reduce prescription opioid abuse and promote treatment options, we are committed to working with policymakers, including the leadership and staff of the Food and Drug Administration (FDA), to address this complex and urgent public health challenge. Our comments emphasize core principles that we believe will enable the FDA to establish an effective pathway for both generic and branded products and that will best serve patients.

View Full Letter